Consort Partners is a public relations and marketing firm that provides services to technology companies.

Consort Partners

Consort Partners is a boutique public relations firm founded by former C-suite tech execs who understand the value and impact of strategic PR. 

Consort is known for building the profile of 10x Genomics (Nasdaq: TXG) leading to their IPO in September 2019 (the biggest biotech IPO in 2019), the meteoric rise of King Digital (NYSE: KING), from far before their smash hit Candy Crush Saga through their dominance of social games, and were entrusted to help Pinterest (NYSE: PINS) expand their appeal into new audiences and categories. We are also the PR agency-of-record partner for Unity Technologies, Udacity, TaskRabbit, BBVA, Huddl.ai, Fort Ross Ventures, GV, MindMaze, Varo Money and more. 

When we work with you, we bring our team of former journalists and editors, combined with our SVP-level and above PR execs to partner at a strategic level to waste no time in cultivating results.

The rally shooting earlier this month has sparked fear and unease among many Americans, who were already feeling the mental strain from the build-up to the election.

In an interview with KTVU 2 FOX, Freespira CCO Robert Cuyler, PhD, discusses strategies for coping with traumatic information and highlights the importance of taking breaks from the news to protect your mental health.

#mentalhealth #trauma #anxiety #PTSD

https://lnkd.in/eXCeN9nM

Today, we're excited to announce our partnership with The Ohio State University Wexner Medical Center! Taking place over a four-year period, the Ohio State Genomic Health program will enroll 100,000 participants to screen for hereditary health risks seen in genetic diseases such as breast, ovarian, and colorectal cancers, in addition to genetic variants for high cholesterol.

James Lu, M.D. Ph.D, CEO and co-founder of Helix: “Partnering with the Ohio State University, one of the nation’s top-ranked academic medical centers, will provide vital information about whether patients have an increased risk of disease. Our other programs have found that 1 in 75 participants received a positive result for one of these serious, actionable genetic conditions. We are proud to partner with Ohio State to positively impact public health across the state and enable individuals to take greater control of their health.”

Read more about the largest precision health initiative in Ohio: https://bit.ly/3WjS6Ur

Q Bio has developed a groundbreaking new approach to #MRI that enables the collection of quantified, reproducible data, which can allow clinicians to monitor changes in a patient's #health over time. The company has raised an additional $27M from existing investors and joined by new participant TELUS Global Ventures (TGV) to help accelerate their plans to bring this new scanner to market, reports Mohana Ravindranath in this STAT exclusive.

𝐃𝐨𝐧’𝐭 𝐦𝐢𝐬𝐬 𝐨𝐮𝐫 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 𝐭𝐡𝐢𝐬 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲 𝐰𝐢𝐭𝐡 Geoff Johnson, MD, PhD and Kathy Spencer-Pike 👉 𝐖𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬’𝐬 𝐩𝐮𝐫𝐬𝐮𝐢𝐭 𝐨𝐟 𝐚 𝐥𝐚𝐛𝐞𝐥 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐟𝐨𝐫 𝐏𝐥𝐮𝐯𝐢𝐜𝐭𝐨 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐲 𝐦𝐞𝐚𝐧 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐟𝐢𝐞𝐥𝐝 𝐨𝐟 𝐫𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲?

Register now: https://hubs.ly/Q02GLTxB0

"By leveraging unbiased #proteomics, scientists can begin to identify novel #biomarkers for diseases such as cancer and Alzheimer's disease -- and in the future, develop those biomarkers into clinically relevant and reliable diagnostic tests." 

In his article in Technology Networks, Seer's SVP of Research Asim Siddiqui explains how the science of proteomics is advancing biomarker discovery, and what it means for human #health.  https://lnkd.in/g-NzDCvW

Metric
Company Name	Consort Partners
Symbol
MSH ID	COM:CONSORTPARTNERS
Market	PRIVATE
Sector	Commercial & Professional Services
Industry	Public Relations and Marketing
Country	US
Stage
Employee Count	9
Website	consortpartners.com
LinkedIn	consort-partners
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CONSORTPARTNERS

Consort Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue